Allergy Therapeutics plc

("Allergy Therapeutics", or the "Group")

Exercise of Options and Total Voting Rights

19 December 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that to rectify an administrative oversight in relation to the exercise of options under the Company's block admission facility, the Company has made an application to the London Stock Exchange for 709,638 ordinary shares of 0.1 pence each to be admitted to trading on AIM. It is expected that these shares will be admitted to trading on AIM on or around 27 December 2024.

The Group's total issued ordinary share capital remains unchanged at 4,766,439,938 ordinary shares, with no shares held in treasury. This figure may be used by shareholders as the denominator for their calculations regarding disclosure obligations.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.